<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538014</url>
  </required_header>
  <id_info>
    <org_study_id>18426A</org_study_id>
    <nct_id>NCT04538014</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain</brief_title>
  <official_title>Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-Lu AF88434 Investigating Blood-brain Barrier Penetration, Safety, and Tolerability of Lu AF88434 in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how much of Lu AF88434 will get into the blood and the brain in&#xD;
      healthy men&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of the following parts:&#xD;
&#xD;
        -  a Screening Visit&#xD;
&#xD;
        -  an MRI scanning visit&#xD;
&#xD;
        -  an in-clinic stay which includes: a Safety Baseline one day prior to dosing, a one-day&#xD;
           [11C]-Lu AF88434 imaging session consisting of a baseline PET measurement and a&#xD;
           post-dose PET measurement conducted after the administration of a single oral dose of Lu&#xD;
           AF88434, pharmacokinetic (PK) sampling and safety assessments throughout the period&#xD;
&#xD;
        -  a Follow-up Visit 7 days after dosing&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2020</start_date>
  <completion_date type="Actual">October 21, 2020</completion_date>
  <primary_completion_date type="Actual">October 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total distribution volume (VT) of [11C]-Lu AF88434</measure>
    <time_frame>At baseline and post-dose on Day 1</time_frame>
    <description>Whole-brain distribution volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C(PET) of Lu AF88434</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean plasma concentration of Lu AF88434 during the post-dose PET measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC(0-inf)) of Lu AF88434</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration time curve of Lu AF88434 from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Lu AF88434</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum observed plasma concentration of Lu AF88434</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AF88434</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF88434</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Lu AF88434</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]-Lu AF88434</intervention_name>
    <description>[11C]-Lu AF88434, and a radioactive dose not exceeding 400 MBq at each PET examination, intravenous bolus injection</description>
    <arm_group_label>Lu AF88434</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has a BMI ≥18.5 and ≤30.0 kg/m2 at the Screening Visit and at the Baseline&#xD;
             Visit&#xD;
&#xD;
          -  The subject has a normal MRI performed during the screening period, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  The subject is, in the opinion of the investigator, generally healthy based on the&#xD;
             assessment of medical history, physical examination, vital signs, body weight, ECG,&#xD;
             and the results of the haematology, clinical chemistry, urinalysis, serology, and&#xD;
             other laboratory tests&#xD;
&#xD;
          -  The subject can tolerate confined spaces for prolonged periods of time&#xD;
&#xD;
          -  The subject is suitable for radial artery blood sampling and cannulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any concurrent disorder that may affect the particular target or&#xD;
             absorption, distribution, or elimination of the Investigational Medicinal Product&#xD;
             (IMP)&#xD;
&#xD;
        Other in- or exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International Northwick Park Hospital (Level 7)</name>
      <address>
        <city>Middlesex</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

